Peer-Reviewed Publications

• Roy A, Koike E T, Joshi S A, et al. (2023). Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model. JCI Insight Apr 18;e164768.
• Roy A, Narkar VA, Kumar A (2023). Emerging role of TAK1 in the regulation of skeletal muscle mass. BioEssays, 45, e2300003.
• Sopariwala, DH, Rios, AS, Pei, G, Roy A et al. (2022). Innately expressed estrogen-related receptors in the skeletal muscle are indispensable for exercise fitness. FASEB Journal. 2023; 37:e22727.
• Tomaz da Silva M, Joshi S A, Koike E T, Roy A, et al. (2022). Targeted ablation of Fn14 receptor improves exercise capacity and inhibits neurogenic muscle atrophy. FASEB Journal. 12, 36.
• Roy A, Kumar A. (2022). Supraphysiological activation of TAK1 promotes skeletal muscle growth and mitigates neurogenic atrophy. Nature Communications 13, 2201.
• Roy A, Tomaz da Silva M, Bhat R, Bohnert KR, Iwawaki T, and Kumar A. (2021). The IRE1/XBP1 signaling axis promotes skeletal muscle regeneration through a cell non-autonomous mechanism. eLife.10:e73215.
• Parveen A, Bohnert KR, Tomaz da Silva M, Wen Y, Bhat R, Roy A, Kumar A. (2021). MyD88-mediated signaling intercedes in neurogenic muscle atrophy through multiple mechanisms. FASEB Journal. Aug;35(8):e21821.
• Parveen A, Wen Y, Roy A, Kumar A. (2021). Therapeutic Targeting of Pten in Duchenne Muscular Dystrophy Molecular Therapy: the Journal of the American Society of Gene Therapy, 29(1):8-9
• Roy A, Sharma AK, Nellore K, Narkar VA, Kumar A. (2020). TAK1 preserves skeletal muscle mass and mitochondrial function through redox homeostasis. FASEB BioAdvances. 2 (9), 538-553.
• Roy A, Kumar A. (2019). ER stress and unfolded protein response in cancer cachexia. Cancers (Basel)11 (12), 1929.
• Bohnert KR, Goli P, Roy A, Sharma AK, Xiong G, Gallot YS, Kumar A. (2019). TLR/MyD88/XBP1 signaling axis mediates skeletal musclewastingduringcancercachexia.MolecularCellBiology.39:e00184-19.
• RoyA,SarkerS,UpadhyayP,PalA,AdhikaryA,JanaK,RayM. (2018). Methylglyoxalatmetronomicdosessensitizesbreastcancer cells to doxorubicin and cisplatin causing synergistic induction of programmed cell death and inhibition of stemness. Biochemical Pharmacology.156, 322–339.
• Roy A, Ahir M, Bhattacharya S, et al. (2017). Induction of Mitochondrial Apoptotic Pathway in Triple Negative Breast Carcinoma Cells by Methylglyoxal via Generation of Reactive Oxygen Species. Molecular Carcinogenesis;56(9):2086-2103. doi:10.1002/mc.22665.
• PalA,RoyA,RayM. (2016). CreatineSupplementationwithMethylglyoxal:aPotentTherapyforCancerinExperimentalModels. Amino Acids;48(8):2003–2013.
• Pal A, Talukdar D, Roy A, et al. (2015). Nanofabrication of Methylglyoxal with Chitosan Biopolymer: a Potential Tool for Enhancement of its Anticancer Effect. International Journal of Nanomedicine;10:3499–3518.
• RoyA, Ray M, Jana K. (2013). Cancer stem cells, Wnt, Hedgehog and Notch signaling, the role of dietary phytochemicals: new insights for cancer therapy. Transl Med 2013 3,e125.

Selected Presentations at Conferences

• Roy A, Jana K, Ray M. Anticancer Activity of Methylglyoxal on Triple Negative Breast Carcinoma is primarily mediated by Reactive Oxygen Species – Poster presentation at the 19th International Conference on Oxidative Stress Reduction, Redox Homeostasis and Antioxidants, Paris Redox 2017 organized by The Sorbonne University Pierre and Marie Curie, Paris, France.
• Roy A, Ray M. Preclinical Studies of Nanofabricated Methylglyoxal; Combination with Conventional Chemotherapeutic drugs and Effects on Cancer Stem Cells – Oral presentation at the 1st International Conference on Clinical Trial & Innovative Therapeutics held on July 2017 organized by SATA, SA and Larkin University, USA at Cape Town, South Africa.
• Roy A, Ghosh A, Ray M. Methylglyoxal Induces Mitochondria Dependent Apoptosis in Sarcoma and Carcinoma – Poster presentation at the EMBO Workshop on Mitochondria, Apoptosis and Cancer 2017 organized by the Joseph Stephan Institute, Ljubljana, Slovenia at Bled, Slovenia.
• Roy A, Kumar A. TAK1 promotes skeletal muscle growth and inhibits neurogenic muscle atrophy. Oral presentation at the PPS Research Symposium 2021, College of Pharmacy University of Houston. USA.
• Roy A, Kumar A. TAK1 is a positive regulator of skeletal muscle mass. Oral presentation at the PPS Research Symposium 2022, College of Pharmacy University of Houston. USA.
• Roy A, Koike TE. Joshi AS et. al. Temporal regulation of TAK1 mitigates disease progression in a DMD mouse model. Poster presentation at the Advances in Skeletal Muscle Biology Conference, Myology Institute, University of Florida, USA.